These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

962 related items for PubMed ID: 24457069

  • 1. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.
    Breast Cancer Res; 2014 Jan 23; 16(1):R12. PubMed ID: 24457069
    [Abstract] [Full Text] [Related]

  • 2. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.
    Breast Cancer Res; 2011 Mar 01; 13(2):R21. PubMed ID: 21362200
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
    Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M.
    Breast Cancer Res; 2012 Oct 17; 14(5):R132. PubMed ID: 23075476
    [Abstract] [Full Text] [Related]

  • 4. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA.
    Mol Cancer Ther; 2015 Sep 17; 14(9):2035-48. PubMed ID: 26116361
    [Abstract] [Full Text] [Related]

  • 5. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.
    Breast Cancer Res; 2014 Sep 11; 16(5):430. PubMed ID: 25212826
    [Abstract] [Full Text] [Related]

  • 6. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC.
    Mol Cancer Ther; 2015 Nov 11; 14(11):2508-18. PubMed ID: 26358751
    [Abstract] [Full Text] [Related]

  • 7. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK, Ribas R, Pancholi S, Nikitorowicz-Buniak J, Simigdala N, Dowsett M, Johnston SR, Martin LA.
    PLoS One; 2016 Nov 11; 11(6):e0157397. PubMed ID: 27308830
    [Abstract] [Full Text] [Related]

  • 8. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE, Lalani AS, Dowsett M, Johnston SR, Martin LA.
    Breast Cancer Res; 2018 Jun 08; 20(1):44. PubMed ID: 29880014
    [Abstract] [Full Text] [Related]

  • 9. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC.
    PLoS One; 2015 Jun 08; 10(7):e0131400. PubMed ID: 26148118
    [Abstract] [Full Text] [Related]

  • 10. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.
    Mol Cancer Res; 2013 Oct 08; 11(10):1269-78. PubMed ID: 23814023
    [Abstract] [Full Text] [Related]

  • 11. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
    Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA.
    Ann Oncol; 2007 Aug 08; 18(8):1323-8. PubMed ID: 17693645
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG.
    PLoS One; 2013 Aug 08; 8(11):e80070. PubMed ID: 24244612
    [Abstract] [Full Text] [Related]

  • 13. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I, Lantieri L, Wolkenstein P, Vidaud M, Pasmant E, Chapuis N, Parfait B.
    Oncotarget; 2016 Jun 14; 7(24):35753-35767. PubMed ID: 26840085
    [Abstract] [Full Text] [Related]

  • 14. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
    Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA.
    Mol Cancer Ther; 2009 Apr 14; 8(4):742-53. PubMed ID: 19372546
    [Abstract] [Full Text] [Related]

  • 15. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
    Kauffman EC, Lang M, Rais-Bahrami S, Gupta GN, Wei D, Yang Y, Sourbier C, Srinivasan R.
    BMC Cancer; 2019 Sep 13; 19(1):917. PubMed ID: 31519159
    [Abstract] [Full Text] [Related]

  • 16. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M, Gillick JL, Neil J, Tobias M, Thwing ZE, Murali R.
    Adv Biol Regul; 2015 Jan 13; 57():64-74. PubMed ID: 25442674
    [Abstract] [Full Text] [Related]

  • 17. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
    Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME.
    Mol Cancer; 2014 Oct 06; 13():229. PubMed ID: 25283550
    [Abstract] [Full Text] [Related]

  • 18. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.
    Int J Cancer; 2010 Jan 15; 126(2):545-62. PubMed ID: 19609946
    [Abstract] [Full Text] [Related]

  • 19. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
    Hall BA, Kim TY, Skor MN, Conzen SD.
    Breast Cancer Res Treat; 2012 Sep 15; 135(2):469-79. PubMed ID: 22842983
    [Abstract] [Full Text] [Related]

  • 20. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
    Brufsky AM.
    Breast J; 2014 Sep 15; 20(4):347-57. PubMed ID: 24861776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.